576 related articles for article (PubMed ID: 12671893)
1. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.
Abad C; Martinez C; Juarranz MG; Arranz A; Leceta J; Delgado M; Gomariz RP
Gastroenterology; 2003 Apr; 124(4):961-71. PubMed ID: 12671893
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide.
Gonzalez-Rey E; Delgado M
Gastroenterology; 2006 Dec; 131(6):1799-811. PubMed ID: 17087944
[TBL] [Abstract][Full Text] [Related]
3. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses.
González MA; Gonzalez-Rey E; Rico L; Büscher D; Delgado M
Gastroenterology; 2009 Mar; 136(3):978-89. PubMed ID: 19135996
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic action of ghrelin in a mouse model of colitis.
Gonzalez-Rey E; Chorny A; Delgado M
Gastroenterology; 2006 May; 130(6):1707-20. PubMed ID: 16697735
[TBL] [Abstract][Full Text] [Related]
5. VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4.
Arranz A; Juarranz Y; Leceta J; Gomariz RP; Martínez C
Peptides; 2008 Jun; 29(6):948-56. PubMed ID: 18359536
[TBL] [Abstract][Full Text] [Related]
6. Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis.
Arranz A; Abad C; Juarranz Y; Torroba M; Rosignoli F; Leceta J; Gomariz RP; Martínez C
Ann N Y Acad Sci; 2006 Jul; 1070():129-34. PubMed ID: 16888154
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn's Disease Mouse Model.
Lv QK; Liu JX; Li SN; Gao YJ; Lv Y; Xu ZP; Huang BX; Xu SY; Yang DX; Zeng YL; Liu DF; Wang W
Int J Mol Sci; 2015 Nov; 16(11):26654-66. PubMed ID: 26561804
[TBL] [Abstract][Full Text] [Related]
8. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile.
Daniel C; Sartory NA; Zahn N; Radeke HH; Stein JM
J Pharmacol Exp Ther; 2008 Jan; 324(1):23-33. PubMed ID: 17911375
[TBL] [Abstract][Full Text] [Related]
9. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice.
Daniel C; Radeke HH; Sartory NA; Zahn N; Zuegel U; Steinmeyer A; Stein J
J Pharmacol Exp Ther; 2006 Nov; 319(2):622-31. PubMed ID: 16914561
[TBL] [Abstract][Full Text] [Related]
10. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP.
Abad C; Juarranz Y; Martinez C; Arranz A; Rosignoli F; García-Gómez M; Leceta J; Gomariz RP
Inflamm Bowel Dis; 2005 Jul; 11(7):674-84. PubMed ID: 15973123
[TBL] [Abstract][Full Text] [Related]
11. Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis.
Zuo L; Huang Z; Dong L; Xu L; Zhu Y; Zeng K; Zhang C; Chen J; Zhang J
Gut; 2010 Apr; 59(4):470-9. PubMed ID: 19951904
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide as a healing mediator in Crohn's disease.
Arranz A; Abad C; Juarranz Y; Leceta J; Martinez C; Gomariz RP
Neuroimmunomodulation; 2008; 15(1):46-53. PubMed ID: 18667799
[TBL] [Abstract][Full Text] [Related]
13. Treatment with bindarit, an inhibitor of MCP-1 synthesis, protects mice against trinitrobenzene sulfonic acid-induced colitis.
Bhatia M; Landolfi C; Basta F; Bovi G; Ramnath RD; de Joannon AC; Guglielmotti A
Inflamm Res; 2008 Oct; 57(10):464-71. PubMed ID: 18827968
[TBL] [Abstract][Full Text] [Related]
14. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.
Sun X; Somada S; Shibata K; Muta H; Yamada H; Yoshihara H; Honda K; Nakamura K; Takayanagi R; Tani K; Podack ER; Yoshikai Y
Gastroenterology; 2008 Feb; 134(2):447-58. PubMed ID: 18242212
[TBL] [Abstract][Full Text] [Related]
15. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice.
Zhao J; de Vera J; Narushima S; Beck EX; Palencia S; Shinkawa P; Kim KA; Liu Y; Levy MD; Berg DJ; Abo A; Funk WD
Gastroenterology; 2007 Apr; 132(4):1331-43. PubMed ID: 17408649
[TBL] [Abstract][Full Text] [Related]
16. RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease.
Bourreille A; Doubremelle M; de la Blétière DR; Segain JP; Toquet C; Buelow R; Galmiche JP
Scand J Gastroenterol; 2003 May; 38(5):526-32. PubMed ID: 12795464
[TBL] [Abstract][Full Text] [Related]
17. N-(3', 4'-dimethoxycinnamonyl) anthranilic acid alleviated experimental colitis by inhibiting autoimmune response and inducing CD4+ CD25+ regulatory T cells production.
Wen Q; Zhou L; Chen H; Zhang Y
J Gastroenterol Hepatol; 2013 Aug; 28(8):1330-8. PubMed ID: 23663055
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide reduces 2,4,6-trinitrobenzene sulfonic acid-induced murine colitis via nuclear factor-κB down-regulation and caspase-3 activation.
Singer M; Trugnan G; Chelbi-Alix MK
Innate Immun; 2011 Aug; 17(4):365-74. PubMed ID: 20693187
[TBL] [Abstract][Full Text] [Related]
19. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
[TBL] [Abstract][Full Text] [Related]
20. AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis.
Bai A; Ma AG; Yong M; Weiss CR; Ma Y; Guan Q; Bernstein CN; Peng Z
Biochem Pharmacol; 2010 Dec; 80(11):1708-17. PubMed ID: 20797389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
